Primary adrenal insufficiency during immune checkpoint inhibitor treatment: Case reports and review of the literature

Carlos Salinas; Alex Renner; Carlos Rojas; Suraj Samtani; Mauricio Burotto

doi:10.1159/000507652

Primary adrenal insufficiency during immune checkpoint inhibitor treatment: Case reports and review of the literature

Carlos Salinas, Alex Renner, Carlos Rojas, Suraj Samtani, Mauricio Burotto

Research output: Contribution to journal › Article › peer-review

Abstract

Published by S. Karger AG, Basel. As the indications and clinical use of immune checkpoint inhibitors increase, it is expected that we will face some of their less frequently reported complications. Primary adrenal insufficiency is one of them, and given its unspecific symptoms and potentially serious consequences, it is important to have a high degree of clinical suspicion. We present 3 cases and a review of the literature concerning its main clinical characteristics, diagnostics, and management.

Original language	American English
Pages (from-to)	621-626
Number of pages	6
Journal	Case Reports in Oncology
DOIs	https://doi.org/10.1159/000507652
State	Published - 1 Jan 2020

Keywords

Immune-related adverse events
Ipilimumab
Nivolumab
Primary adrenal insufficiency

Access to Document

10.1159/000507652

Fingerprint Dive into the research topics of 'Primary adrenal insufficiency during immune checkpoint inhibitor treatment: Case reports and review of the literature'. Together they form a unique fingerprint.

Cite this

@article{79b03a762a004aeea96626ca1c09365d,

title = "Primary adrenal insufficiency during immune checkpoint inhibitor treatment: Case reports and review of the literature",

abstract = "Published by S. Karger AG, Basel. As the indications and clinical use of immune checkpoint inhibitors increase, it is expected that we will face some of their less frequently reported complications. Primary adrenal insufficiency is one of them, and given its unspecific symptoms and potentially serious consequences, it is important to have a high degree of clinical suspicion. We present 3 cases and a review of the literature concerning its main clinical characteristics, diagnostics, and management.",

keywords = "Immune-related adverse events, Ipilimumab, Nivolumab, Primary adrenal insufficiency, Immune-related adverse events, Ipilimumab, Nivolumab, Primary adrenal insufficiency",

author = "Carlos Salinas and Alex Renner and Carlos Rojas and Suraj Samtani and Mauricio Burotto",

year = "2020",

month = jan,

day = "1",

doi = "10.1159/000507652",

language = "American English",

pages = "621--626",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Primary adrenal insufficiency during immune checkpoint inhibitor treatment: Case reports and review of the literature

AU - Salinas, Carlos

AU - Renner, Alex

AU - Rojas, Carlos

AU - Samtani, Suraj

AU - Burotto, Mauricio

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Published by S. Karger AG, Basel. As the indications and clinical use of immune checkpoint inhibitors increase, it is expected that we will face some of their less frequently reported complications. Primary adrenal insufficiency is one of them, and given its unspecific symptoms and potentially serious consequences, it is important to have a high degree of clinical suspicion. We present 3 cases and a review of the literature concerning its main clinical characteristics, diagnostics, and management.

AB - Published by S. Karger AG, Basel. As the indications and clinical use of immune checkpoint inhibitors increase, it is expected that we will face some of their less frequently reported complications. Primary adrenal insufficiency is one of them, and given its unspecific symptoms and potentially serious consequences, it is important to have a high degree of clinical suspicion. We present 3 cases and a review of the literature concerning its main clinical characteristics, diagnostics, and management.

KW - Immune-related adverse events

KW - Ipilimumab

KW - Nivolumab

KW - Primary adrenal insufficiency

KW - Immune-related adverse events

KW - Ipilimumab

KW - Nivolumab

KW - Primary adrenal insufficiency

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087169863&origin=inward

U2 - 10.1159/000507652

DO - 10.1159/000507652

M3 - Article

SP - 621

EP - 626

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

ER -